Novo falls behind Eli Lilly in market race as investors react to Q3 results

A year ago the competition between Eli Lilly and Novo was described as the fiercest in the industry. Recent commentary suggests the rivalry has become increasingly one‑sided, with Novo struggling to keep pace.

Investors appear to be signaling this shift through their reactions to each company's third‑quarter earnings, with Lilly’s stock performing better than Novo’s.

Analysts interpret the market response as evidence that Novo’s effort to catch Lilly may already be lost, highlighting the challenges the company faces in closing the gap.